On the basis of these findings, researchers have theorized that NAT10 could serve as a potential target and prognostic biomarker for cancer treatment, including multiple myeloma and squamous cell carcinoma of the head and neck (HNSCC) [79, 117]. Here, NAT10 is linked to plasma cell myeloma.